CA2898958A1 - Composition comprising an encapsulated antagomir - Google Patents

Composition comprising an encapsulated antagomir Download PDF

Info

Publication number
CA2898958A1
CA2898958A1 CA2898958A CA2898958A CA2898958A1 CA 2898958 A1 CA2898958 A1 CA 2898958A1 CA 2898958 A CA2898958 A CA 2898958A CA 2898958 A CA2898958 A CA 2898958A CA 2898958 A1 CA2898958 A1 CA 2898958A1
Authority
CA
Canada
Prior art keywords
mir
seq
sequence
nucleotide identity
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2898958A
Other languages
English (en)
French (fr)
Inventor
Miguel-Angel Asin
Eulalia Ferret
Amadeo Perez
Neus Bellera Gotarda
Antonio Rodriguez Sinovas
Ignasi Barba Vert
Antonio David Garcia-Dorado Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut de Recerca Hospital Universitari Vall dHebron, Pierre Fabre Medicament SA filed Critical Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Publication of CA2898958A1 publication Critical patent/CA2898958A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2898958A 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir Abandoned CA2898958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
EP13305082.3 2013-01-24
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
CA2898958A1 true CA2898958A1 (en) 2014-07-31

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2898958A Abandoned CA2898958A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Country Status (16)

Country Link
US (1) US20150352055A1 (enExample)
EP (2) EP2759595B1 (enExample)
JP (1) JP2016506923A (enExample)
KR (1) KR20160018451A (enExample)
CN (1) CN105229151A (enExample)
AU (1) AU2014208419A1 (enExample)
BR (1) BR112015017650A2 (enExample)
CA (1) CA2898958A1 (enExample)
ES (2) ES2606636T3 (enExample)
HK (1) HK1219753A1 (enExample)
HU (1) HUE032125T2 (enExample)
MX (1) MX2015009323A (enExample)
PL (1) PL2759595T3 (enExample)
RU (1) RU2668794C2 (enExample)
WO (1) WO2014115103A1 (enExample)
ZA (1) ZA201505602B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス， インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
EP3247716A4 (en) * 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
WO2018183127A1 (en) * 2017-03-25 2018-10-04 MiRagen Therapeutics, Inc. Mir-92 inhibitors for treatment of heart failure
CN113490488A (zh) * 2019-03-14 2021-10-08 M技术株式会社 Plga微粒子、其缓释制剂以及其制造方法
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
US8288356B2 (en) * 2007-10-04 2012-10-16 Santaris Pharma A/S MicroRNAs
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
CA2763156A1 (en) * 2009-05-20 2010-11-25 Board Of Regents, The University Of Texas System Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure

Also Published As

Publication number Publication date
PL2759595T3 (pl) 2017-09-29
ES2606636T3 (es) 2017-03-24
KR20160018451A (ko) 2016-02-17
EP2948551A1 (en) 2015-12-02
MX2015009323A (es) 2016-04-04
CN105229151A (zh) 2016-01-06
BR112015017650A2 (pt) 2017-11-21
HK1219753A1 (zh) 2017-04-13
ZA201505602B (en) 2017-05-31
EP2759595A1 (en) 2014-07-30
WO2014115103A1 (en) 2014-07-31
US20150352055A1 (en) 2015-12-10
HUE032125T2 (en) 2017-08-28
JP2016506923A (ja) 2016-03-07
RU2015134770A (ru) 2017-03-03
RU2668794C2 (ru) 2018-10-02
EP2759595B1 (en) 2016-09-14
ES2688160T3 (es) 2018-10-31
AU2014208419A1 (en) 2015-08-13
EP2948551B1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
EP2948551B1 (en) Composition comprising an encapsulated antagomir
EP2552454B1 (en) ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS
JP2015521626A5 (enExample)
US12234455B2 (en) Therapeutic oligonucleotides
JP2015525081A5 (enExample)
JP2013514372A (ja) 虚血および虚血−再灌流傷害におけるマイクロｒｎａ調節
JP2011256204A5 (enExample)
ES3001019T3 (es) Inhibidores del MICRO-RNA 22
KR20180005546A (ko) 약물이 탑재된 엑소좀 또는 나노베지클을 이용한 약학적 조성물
EP3329004B1 (en) Therapeutic oligonucleotides
Wang et al. MicroRNA delivery based on nanoparticles of cardiovascular diseases
CN102416184A (zh) microRNA-1的反义锁核苷酸序列在制备预防或治疗心肌梗死后心衰药物中的应用
US20240417734A1 (en) Methods for Treating Glioblastoma by Targeting Oncomirs
JPWO2015133637A1 (ja) マイクロｒｎａ封入ナノ粒子及びその医薬用途
EP4634386A1 (en) Antisense oligonucleotide analogs of mir-29 and uses thereof
JP7639035B2 (ja) 骨量減少または筋機能低下に関連する病的状態を治療する際に使用するためのマイクロｒｎａ１９ａ／１９ｂ
BR112018001782B1 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
BR122024021791A2 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200123